Image by Adeolu Eletu


Longeveron To Present At The 2018 Cell & Gene Meeting On The Mesa


October 03, 2018


Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa October 3-5 in La Jolla, California



Longeveron LLC 

Oct. 03, 2018 13:33 ET

MIAMI, Oct. 3, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa October 3-5 in La Jolla, California.


This conference, at the Estancia La Jolla Hotel & Spa, is the largest partnering meeting organized specifically for the cell and gene therapy sector, providing the opportunity for participants to establish key relationships and accelerate business development.


Joshua Hare, M.D., Longeveron Co-Founder and Chief Science Officer, will provide an overview of Longeveron’s progress in developing pioneering stem cell treatments for aging-related diseases, including Aging Frailty and Alzheimer’s, and discuss the company’s clinical research.  The Longeveron presentation is scheduled for Thursday, Oct. 4, at 4:45 PM PT.


“We welcome the opportunity to present our advancements in stem cell regenerative medicine at this key event that brings together company executives, experts and researchers, as well as investors in the emerging healthcare and biotech sector,” Dr. Hare said.


Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases.  In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease.  The company is now recruiting for an expanded Phase 2b Aging Frailty study.


Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients.  Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.


Organized by ARM and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.  The event’s Partnering Forum on October 3-4 features more than 70 dedicated company presentations in addition to over 90 panelists and featured speakers.


A live video webcast of all company presentations will be available at and will also be published on the conference website shortly after the event.


About Longeveron 


Longeveron ( is a regenerative medicine therapy company founded in 2014.  Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life.  The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund.  Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.


For more information about the clinical trials

Longeveron is sponsoring, visit

or Longeveron’s website


SOURCE Longeveron LLC


Related Links